X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Sun Pharma with IPCA Labs - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

SUN PHARMA vs IPCA LABS - Comparison Results

SUN PHARMA    Change

Sun Pharma holds 3.7% share of the domestic pharma market (as per the latest ORG IMS MAT data) and has a strong presence in the lifestyle therapeutic segments. The company started focusing on the exports market in FY02, when it increased its stake to... More

IPCA LABS 
   Change

Ipca Laboratories is an integrated pharmaceutical company with presence in intermediates, APIs and formulations. The company has a strong focus on exports, catering to the US, Europe and the semi-regulated markets of the CIS, Africa and Asia. The com... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    SUN PHARMA IPCA LABS SUN PHARMA/
IPCA LABS
 
P/E (TTM) x 38.3 29.7 129.0% View Chart
P/BV x 4.1 3.5 116.1% View Chart
Dividend Yield % 0.3 0.1 231.9%  

Financials

 SUN PHARMA   IPCA LABS
EQUITY SHARE DATA
    SUN PHARMA
Mar-18
IPCA LABS
Mar-18
SUN PHARMA/
IPCA LABS
5-Yr Chart
Click to enlarge
High Rs701695 100.7%   
Low Rs433400 108.3%   
Sales per share (Unadj.) Rs110.4260.2 42.4%  
Earnings per share (Unadj.) Rs11.019.0 57.9%  
Cash flow per share (Unadj.) Rs17.233.1 52.1%  
Dividends per share (Unadj.) Rs2.001.00 200.0%  
Dividend yield (eoy) %0.40.2 193.2%  
Book value per share (Unadj.) Rs158.8213.0 74.5%  
Shares outstanding (eoy) m2,399.26126.20 1,901.2%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x5.12.1 243.9%   
Avg P/E ratio x51.628.9 178.9%  
P/CF ratio (eoy) x32.916.6 198.6%  
Price / Book Value ratio x3.62.6 138.8%  
Dividend payout %18.25.3 345.6%   
Avg Mkt Cap Rs m1,360,02169,120 1,967.6%   
No. of employees `00017.813.3 134.2%   
Total wages/salary Rs m53,6717,359 729.3%   
Avg. sales/employee Rs Th14,890.92,477.4 601.1%   
Avg. wages/employee Rs Th3,017.1555.2 543.4%   
Avg. net profit/employee Rs Th1,480.6180.6 819.6%   
INCOME DATA
Net Sales Rs m264,89532,836 806.7%  
Other income Rs m8,388418 2,006.6%   
Total revenues Rs m273,28233,254 821.8%   
Gross profit Rs m56,0814,505 1,244.9%  
Depreciation Rs m14,9981,777 843.9%   
Interest Rs m5,176240 2,154.7%   
Profit before tax Rs m44,2952,905 1,524.6%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m-9,5050-   
Tax Rs m8,452511 1,653.7%   
Profit after tax Rs m26,3382,394 1,100.1%  
Gross profit margin %21.213.7 154.3%  
Effective tax rate %19.117.6 108.5%   
Net profit margin %9.97.3 136.4%  
BALANCE SHEET DATA
Current assets Rs m316,35919,455 1,626.1%   
Current liabilities Rs m198,64310,076 1,971.5%   
Net working cap to sales %44.428.6 155.6%  
Current ratio x1.61.9 82.5%  
Inventory Days Days9598 96.9%  
Debtors Days Days10867 160.9%  
Net fixed assets Rs m213,17820,260 1,052.2%   
Share capital Rs m2,399252 950.6%   
"Free" reserves Rs m378,60626,633 1,421.6%   
Net worth Rs m381,00626,886 1,417.1%   
Long term debt Rs m17,7212,340 757.3%   
Total assets Rs m643,02841,173 1,561.8%  
Interest coverage x9.613.1 73.0%   
Debt to equity ratio x00.1 53.4%  
Sales to assets ratio x0.40.8 51.7%   
Return on assets %4.96.4 76.6%  
Return on equity %6.98.9 77.6%  
Return on capital %10.010.8 93.1%  
Exports to sales %047.6 0.0%   
Imports to sales %014.9 0.0%   
Exports (fob) Rs mNA15,642 0.0%   
Imports (cif) Rs mNA4,884 0.0%   
Fx inflow Rs m40,81615,642 260.9%   
Fx outflow Rs m30,1434,884 617.2%   
Net fx Rs m10,67310,759 99.2%   
CASH FLOW
From Operations Rs m39,0723,411 1,145.4%  
From Investments Rs m-33,708-1,354 2,489.5%  
From Financial Activity Rs m-15,393-1,304 1,180.3%  
Net Cashflow Rs m-7,359753 -977.0%  

Share Holding

Indian Promoters % 63.7 45.9 138.8%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 5.1 11.4 45.0%  
FIIs % 23.0 25.3 90.9%  
ADR/GDR % 0.0 0.0 -  
Free float % 8.3 17.4 47.7%  
Shareholders   133,026 36,892 360.6%  
Pledged promoter(s) holding % 0.5 2.1 24.8%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare SUN PHARMA With:   ABBOTT INDIA  NATCO PHARMA  BIOCON LTD  PFIZER  ALKEM LABORATORIES  

Compare SUN PHARMA With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends 170 Points Lower, Realty and FMCG Stocks Witness Selling(Closing)

After opening the day on a positive note, share markets in India witnessed volatile trading activity and ended in red.

Related Views on News

SUN PHARMA 2017-18 Annual Report Analysis (Annual Result Update)

Sep 19, 2018 | Updated on Sep 19, 2018

Here's an analysis of the annual report of SUN PHARMA for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of SUN PHARMA. Also includes updates on the valuation of SUN PHARMA.

SUN PHARMA Announces Quarterly Results (1QFY19); Net Profit Up 446.1% (Quarterly Result Update)

Aug 16, 2018 | Updated on Aug 16, 2018

For the quarter ended June 2018, SUN PHARMA has posted a net profit of Rs 11 bn (up 446.1% YoY). Sales on the other hand came in at Rs 72 bn (up 16.4% YoY). Read on for a complete analysis of SUN PHARMA's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

More Views on News

Most Popular

Is It the Right Time to Buy Pharma Stocks Now?(The 5 Minute Wrapup)

Sep 12, 2018

Is the pharma sector poised for a comeback? Is the worst over? I believe so.

Want Bigger Returns Than You Thought Possible? This is Where You Should Look(Profit Hunter)

Sep 12, 2018

Richa has discovered the single most profitable opportunity in the market - read on to discover more...

The Secret Of Mirae Asset India Equity Fund's Increasing Popularity(Outside View)

Sep 7, 2018

The prudent investment strategies followed at the fund house has helped Mirae Asset India Equity Fund earn a tag of being a consistent performer, which is in turn gaining popularity among investors.

Should You Be Worried About the Rising Dollar?(Chart Of The Day)

Sep 7, 2018

While the rupee has deprecated by about 5% annually since 1990 against the dollar, the BSE Sensex has returned 14% annually in the same period.

Revenge of the Ratings Agencies(Vivek Kaul's Diary)

Sep 7, 2018

Do you remember when ratings agencies ruled financial markets? Nick explains why he thinks it's time to prepare yourselves for a comeback of the ratings agencies.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

SUN PHARMA SHARE PRICE


Sep 19, 2018 (Close)

TRACK SUN PHARMA

  • Track your investment in SUN PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

SUN PHARMA 8-QTR ANALYSIS

COMPARE SUN PHARMA WITH

MARKET STATS